Among neurological disorders, migraine is a leading cause of disability and significantly contributes to individual and societal burdens owing to pain and environmental sensitivities. Quiz Ref ID The prevalence of migraine is 14.9% in the United States,
1 and 8.4% to 12.7% in Asia.
2 Approximately 25% to 38% of migraineurs need preventive therapy,
3,4 and pharmacotherapies, such as divalproex sodium, topiramate, metoprolol, and propranolol, are recommended for migraine prevention. However, such treatments are often associated with an increased risk of adverse events (AEs), including weight gain, fatigue, sleep disturbance, and gastrointestinal intolerance.
4,5 Excessive use of analgesics or specific antimigraine treatments could cause medication overuse–induced headache and an increase in headache frequency.
3,6 Because of the limitations associated with these conventional treatments, efforts have been made to identify effective, low-risk interventions.